MDXG Stock Analysis: MiMedx | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 631m USD | 12M Return: -38.7% | US6024961012 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.77M
Qual. Beats: 0
Rev. Trend: 83.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MiMedx Group, Inc. is a U.S.-based biotechnology company that develops and commercializes placental tissue allografts processed through its proprietary PURION technology, which preserves the biological and regulatory proteins of human placental tissue. The company operates two main product lines: wound care offerings (including EPIFIX and EPICORD) and surgical and other products (such as AMNIOFIX and AMNIOBURN), serving wound care, burn treatment, and surgical applications across lower extremity repair, plastic surgery, vascular surgery, and orthopedic procedures. Products are sold in the United States through a direct sales force, independent sales agents, individual customers, and independent distributors, and the company maintains a strategic alliance with Vaporox, Inc. for wound care promotion. Founded in 2006 and headquartered in Marietta, Georgia, MiMedx fits within the broader regenerative medicine segment of healthcare, where companies leverage human tissue-based biologics rather than synthetic or small-molecule approaches to address tissue repair and healing. As a small-cap stock in the biotechnology sub-industry, the companys revenue is closely tied to reimbursement decisions, clinical adoption of placental allografts, and ongoing regulatory scrutiny of tissue-based products.
- Wound care segment revenue grows on EPIFIX market penetration
- Surgical recovery sales expand in orthopedic and plastic surgery applications
- Regenerative tissue competition pressures product pricing and margins
| Net Income: 6.24m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -3.44 > 1.0 |
| NWC/Revenue: 46.98% < 20% (prev 46.89%; Δ 0.09% < -1%) |
| CFO/TA 0.16 > 3% & CFO 46.1m > Net Income 6.24m |
| Net Debt (-118.6m) to EBITDA (23.7m): -5.01 < 3 |
| Current Ratio: 5.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (147.8m) vs 12m ago -1.02% < -2% |
| Gross Margin: 78.85% > 18% (prev 81.45%; Δ -2.60% > 0.5%) |
| Asset Turnover: 124.2% > 50% (prev 125.0%; Δ -0.80% > 0%) |
| Interest Coverage Ratio: 6.75 > 6 (EBIT TTM 12.0m / Interest Expense TTM 1.78m) |
| A: 0.59 (Total Current Assets 205.4m - Total Current Liabilities 38.5m) / Total Assets 281.0m |
| B: -0.24 (Retained Earnings -68.4m / Total Assets 281.0m) |
| C: 0.04 (EBIT TTM 12.0m / Avg Total Assets 286.1m) |
| D: 3.32 (Book Value of Equity 216.0m / Total Liabilities 65.0m) |
| Altman-Z'' = 6.87 = AAA |
| DSRI: 0.61 (Receivables 41.3m/69.2m, Revenue 355.2m/363.8m) |
| GMI: 1.03 (GM 81.45% / 78.85%) |
| AQI: 1.22 (AQ_t 0.25 / AQ_t-1 0.21) |
| SGI: 0.98 (Revenue 355.2m / 363.8m) |
| TATA: -0.14 (NI 6.24m - CFO 46.1m) / TA 281.0m) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of August 26, 2026, the stock is trading at USD 4.34 with a total of 699,293 shares traded. Over the past week, the price has changed by +0.00%, over one month by +1.88%, over three months by +18.26% and over the past year by -38.70%.
Current recommended Stop Loss: 3.90 (which is 10.1% or 2.6 ATR below the current price).
MiMedx has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy MDXG.
- StrongBuy: 5
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7 | 61.3% |
P/E Trailing = 108.25
P/E Forward = 19.5313
P/S = 1.777
P/B = 2.932
P/EG = 2.875
Revenue TTM = 355.2m USD
EBIT TTM = 12.0m USD
EBITDA TTM = 23.7m USD
Long Term Debt = 15.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 17.2m USD (corrected: LT Debt 15.7m + ST Debt 1.50m)
Net Debt = -118.6m USD (calculated: Debt 17.2m - CCE 135.8m)
Enterprise Value = 512.5m USD (631.1m + Debt 17.2m - CCE 135.8m)
Interest Coverage Ratio = 6.75 (Ebit TTM 12.0m / Interest Expense TTM 1.78m)
EV/FCF = 12.63x (Enterprise Value 512.5m / FCF TTM 40.6m)
FCF Yield = 7.92% (FCF TTM 40.6m / Enterprise Value 512.5m)
FCF Margin = 11.42% (FCF TTM 40.6m / Revenue TTM 355.2m)
Net Margin = 1.76% (Net Income TTM 6.24m / Revenue TTM 355.2m)
Gross Margin = 78.85% ((Revenue TTM 355.2m - Cost of Revenue TTM 75.1m) / Revenue TTM)
Gross Margin QoQ = 68.96% (prev 70.56%)
Tobins Q-Ratio = 1.82 (Enterprise Value 512.5m / Total Assets 281.0m)
Interest Expense / Debt = 10.36% (Interest Expense 1.78m / Debt 17.2m)
Taxrate = 45.91% (5.29m / 11.5m)
NOPAT = 6.51m (EBIT 12.0m * (1 - 45.91%))
Current Ratio = 5.33 (Total Current Assets 205.4m / Total Current Liabilities 38.5m)
Debt / Equity = 0.08 (Debt 17.2m / totalStockholderEquity, last quarter 216.0m)
Debt / EBITDA = -5.01 (Net Debt -118.6m / EBITDA 23.7m)
Debt / FCF = -2.92 (Net Debt -118.6m / FCF TTM 40.6m)
Total Stockholder Equity = 238.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.18% (Net Income 6.24m / Total Assets 281.0m)
RoE = 2.61% (Net Income TTM 6.24m / Total Stockholder Equity 238.6m)
RoCE = 4.73% (EBIT 12.0m / Capital Employed (Equity 238.6m + L.T.Debt 15.7m))
RoIC = 2.88% (NOPAT 6.51m / Invested Capital 226.2m)
WACC = 8.09% (E(631.1m)/V(648.3m) * Re(8.16%) + D(17.2m)/V(648.3m) * Rd(10.36%) * (1-Tc(0.46)))
Discount Rate = 8.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -37.72 | Cagr: -0.66%
[DCF] Terminal Value 73.10% ; FCFF base≈45.2m ; Y1≈39.6m ; Y5≈32.0m
[DCF] Fair Price = 4.34 (EV 513.6m - Net Debt -118.6m = Equity 632.3m / Shares 145.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.66 | # QB: 0
Revenue Correlation: 83.36 | Revenue CAGR: 8.36% | SUE: 0.11 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.01 | Chg30d=N/A | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.05 | Chg30d=+23.86% | Revisions=-40% | GrowthEPS=-111.9% | GrowthRev=-35.5%
EPS next Year (2027-12-31): EPS=0.17 | Chg30d=+20.94% | Revisions=-40% | GrowthEPS=+425.0% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: -67% (up=0, down=6)